Camp4 Therapeutics is advancing a unique RNA Actuating Platform (RAP) designed to upregulate gene expression via antisense oligonucleotides (ASOs) targeting regulatory RNAs. Its lead candidate CMP-002 targets the rare CNS genetic disease SYNGAP1-related disorder, with preclinical validation and GLP toxicology studies underway ahead of planned Phase 1/2 trials in H2 2026. The company reported revenue growth driven by grants and collaborations but with widening net losses due to increased R&D investments. Supported by a solid cash position exceeding $109 million, Camp4 faces risks from regulatory uncertainty, capital needs, and operational dependencies as it advances clinical development.